Reproductive Health, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.
Reproductive Health, PATH, P.O. Box 7404, Kampala, Uganda.
Prev Med. 2018 Sep;114:205-208. doi: 10.1016/j.ypmed.2018.07.012. Epub 2018 Jul 19.
To protect women against cervical cancer, the World Health Organization recommends that women aged 30 to 49 years be screened with tests that detect human papillomavirus (HPV). If the countries that have the greatest burden of this disease-especially those in sub-Saharan Africa-are not to be left behind, we must understand the challenges they face and identify measures that can help them take full advantage now of innovations that are transforming screening services in wealthier countries. We reviewed policy documents and published literature related to Kenya, Tanzania, and Uganda, and met with key personnel from government and nongovernmental organizations. National policy makers understand the value of HPV testing in terms of its superior sensitivity and the programmatic advantages that could result from using self-collected samples. However, while these countries have national cervical cancer prevention strategies, and some have national departments or units for cervical cancer prevention, screening is rare, funding scarce, and quality low. Age guidelines are not strictly followed, with scarce resources being used to screen many women younger than the recommended ages. Published evidence of the benefits of HPV testing-including performance, safety, and cost-effectiveness-must be provided to ministry of health leaders, along with information on anticipated costs for training personnel, purchasing supplies, providing facility space, and maintaining test kits. Despite the obstacles, a joint effort on the part of global and national stakeholders to introduce molecular screening methods can bring better protection to the women who need it most.
为了预防宫颈癌,世界卫生组织建议年龄在 30 岁至 49 岁的女性采用 HPV 检测法进行筛查。如果要避免负担最重的国家(尤其是撒哈拉以南非洲地区的国家)掉队,我们就必须了解它们所面临的挑战,并确定可以帮助这些国家充分利用正在改变较富裕国家筛查服务的创新的措施。我们查阅了与肯尼亚、坦桑尼亚和乌干达有关的政策文件和已发表的文献,并与政府和非政府组织的主要人员进行了会晤。国家政策制定者了解 HPV 检测在敏感度方面的优势,以及使用自我采集样本可能带来的规划优势。然而,虽然这些国家都制定了国家宫颈癌预防战略,其中一些国家还设有国家宫颈癌防治部门或单位,但筛查工作仍十分罕见,资金短缺,质量低下。年龄指导方针并未严格遵循,稀缺资源被用于筛查许多年龄低于建议年龄的女性。必须向卫生部领导提供 HPV 检测效益方面的已发表证据,包括检测的性能、安全性和成本效益,同时还要说明培训人员、购买用品、提供设施空间和维护检测试剂盒的预期费用。尽管存在诸多障碍,但全球和国家利益攸关方共同努力推出分子筛查方法,可以为最需要的妇女提供更好的保护。